Organon and Samsung Bioepis add ustekinumab biosimilar to Canada deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
June 18, 2026 6:00 AM EDTThe amended agreement deepens Organon and Samsung Bioepiss collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology.
To be launched in Canada in 2026
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)-- Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA®, Samsung Bioepiss biosimilar referencing STELARA® (ustekinumab).
This press release features multimedia. View the full release here:... More
